The chimeric fusion transcript detection and identification of a new molecular treatment target based on each histological subtype of Mucoepidermoid carcinoma.

• Project/Area Number: 15K20228
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Otorhinolaryngology
• Research Institution: Juntendo University
• Principal Investigator: FUJIMAKI MITSUHISA 順天堂大学, 医学部, 助教 (10514490)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 粘表皮癌 / CRTC1-MAML2 / 融合遺伝子 / RT-PCR / 唾液腺 / ＣＲＴＣ１－ＭＡＭＬ２ / ＣＲＴＣ３－ＭＡＭＬ２

Outline of Final Research Achievements

Recently it was reported that the expression of CRTC1-MAML2 or CRTC3-MAML2 fusion was found on 40-70% of mucoepidermoid carcinoma. These fusions are becoming the important prognostic marker gene for MEC. We analyzed the positive cases to the fusions that include suspicious cases for histopathological diagnoses. We show the data has improved the diagnostic accuracy of MEC. We analyze the fusions clusters related to bad prognosis group and also protein and RNA related to the cell cycle/tumor suppressor gene/epithelial differentiation. Thus we would like to evaluate the downstream of fusions target genes.